Pages
Products
Synapsin-RFP Lentivirus

Synapsin-RFP Lentivirus

Cat.No. :  LV00974Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Cat. No. LV00974Z
Description This lentivirus contains RFP under the control of human synapsin promoter.
Target Gene RFP
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Lentiviral vectors (LV) in gene therapy can be divided into two categories based on the route of administration: in vivo and in vitro. In the in vivo route, LVs are directly delivered to host cells via intravenous or intracerebral administration. In contrast, the in vitro route utilizes virus-mediated transduction to transduce hematopoietic stem cells (HSCs) isolated from host cells and then reintroduces these modified cells into the same patient. Preclinical studies using mouse models require differentiation of donors and recipients because it is not possible to isolate enough cells from the same mouse for transduction. Local brain administration of LVs has been shown to result in broad and stable transgene expression across different cells, with most brain cells, such as neurons and astrocytes, being transduced in animal experiments. Lentiviral vectors have been used to treat a variety of neurological diseases. The selection of an appropriate promoter is essential to obtain efficient transgene expression within cells. The promoter is the primary cis-acting element located at the start of the gene to be transcribed. Transcription of the target gene is activated by attaching RNA polymerase to the binding site of the promoter. The promoter determines the overall strength of gene expression and directs the targeting specificity of tissues or cells. In the past decade, different promoters, including tissue-specific promoters and housekeeping promoters, have been used to treat neurological diseases.

Copy number variations (CNVs) in genes involved in nervous system development or function are often associated with neuropsychiatric disorders. A CNV located on chromosome 15q13.3 affects the alpha-7 nicotinic acetylcholine receptor subunit (CHRNA7) gene and causes multiple neuropsychiatric disorders with highly variable penetrance. Here, researchers generated induced pluripotent stem cell (iPSC) models from first-degree relatives with 15q13.3 duplications and analyzed their cellular phenotypes to reveal the basis for the different phenotypic manifestations. Potential factors contributing to neuropsychiatric disorders were modeled in iPSC-derived cortical excitatory and inhibitory neurons. AP-derived models uniquely exhibited disruptions in cellular physiology and neurodevelopment that were not observed in unaffected mothers (UM) or unrelated controls. These included enhanced neural progenitor proliferation but impaired neuronal differentiation, maturation, and migration, as well as increased endoplasmic reticulum (ER) stress. Both defective neuronal migration and elevated ER stress could be selectively rescued by different drugs. Neuronal gene expression was also dysregulated in the AP, including decreased expression of genes associated with behavior, psychological impairments, neurite outgrowth, neuronal migration, and Wnt, axon guidance, and GABA receptor signaling. The UM model instead exhibited upregulated gene expression in many of the same pathways, suggesting that molecular compensation may contribute to the lack of a neurodevelopmental phenotype in this model. However, both AP- and UM-derived neurons exhibited common alterations in neuronal function, including increased action potential firing and enhanced cholinergic activity, consistent with increased homomeric CHRNA7 channel activity.

AP-derived neurons (compared to UM) exhibited reduced expression of genes regulating neuronal migration (Figure 1a), suggesting that they may have impaired migration. In vivo, cortical interneurons migrate tangentially from the ventral telencephalon to the cortex. To study the migration of cExN and cIN neurons, the researchers developed a method utilizing the fusion co-culture of two 3D spheroids composed of cExN and cIN. These 3D spheroids were generated by transducing cExNPCs and cINPCs, respectively, with lentiviral synapsin-eGFP or lentiviral synapsin-RFP expression constructs. cExN neurons expressing synapsin-GFP and cIN neurons expressing synapsin-RFP were juxtaposed and migration from one neuron to the other was assessed (Figure 1b). cINs from AP neuroids exhibited reduced migration compared to the other models (Figure 1c-d). In contrast, the migration of AP-derived cExNs was only slightly impaired, whereas UM-derived cExNs exhibited reduced migration compared with the control model, suggesting that migration of both CHRNA7 duplication carriers is somewhat impaired (Figure 1c, e).

Figure 1. Neuronal migration is compromised in AP-derived cINs.Figure 1. Neuronal migration is compromised in AP-derived cINs. (Meganathan K, et al., 2021)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Versatile Applications

This product offers great versatility. We’ve successfully used it in various applications, from basic research to more applied studies, with outstanding results.

Germany

06/27/2022

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction